Cargando…

COVID-19 Vaccine Response in Patients with Hematologic Malignancy: A Systematic Review and Meta-Analysis

Introduction: Emerging data suggests that seroresponse (SR) in patients with hematologic malignancy following COVID-19 vaccination is likely lower than in patients without blood cancer. The objective of this study was to perform a systematic review and meta-analysis on SR in patients with hematologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Inna, Vijenthira, Abi, Betschel, Stephen, Hicks, Lisa K., Cheung, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	905.Outcomes Research-Lymphoid Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701771/ http://dx.doi.org/10.1182/blood-2021-149652

Ejemplares similares

COVID-19 in Children, Adolescents and Young Adults with Hematological Malignancies
por: Parker, Rebecca S, et al.
Publicado: (2021)

Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States
por: Neparidze, Natalia, et al.
Publicado: (2021)

Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study
por: Martinez-Lopez, Joaquin, et al.
Publicado: (2021)

Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology
por: Hicks, Lisa K., et al.
Publicado: (2021)

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
por: Aumann, Shlomzion, et al.
Publicado: (2021)

Effect of COVID-19 Pandemic Control Measures on Diagnoses of Hematologic Cancer Among CMS Population in 2020
por: Smart, Dave, et al.
Publicado: (2021)

Association of Race, Ethnicity, Age and Socioeconomic Status with Access to Virtual Visits within the Brigham & Women's Hospital Division of Hematology during the COVID-19 Pandemic
por: Kwarteng-Siaw, Miriam, et al.
Publicado: (2021)

A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy
por: Choi, Yun, et al.
Publicado: (2021)

Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 “Booster” Vaccination - Observational Data from the LLS National Registry
por: Greenberger, Lee M, et al.
Publicado: (2021)

Clinical Outcomes in Patients with Hematologic Malignancy (HM) and COVID-19
por: Cook, Michael Roderick, et al.
Publicado: (2020)

Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period
por: Neparidze, Natalia, et al.
Publicado: (2021)

Utilizing HealthTree ® Cure Hub's Real-World Data to Assess Treatment Management of Patients with Multiple Myeloma during the COVID-19 Pandemic
por: Sweeney, Nathan W., et al.
Publicado: (2021)

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)
por: Garnica, Marcia, et al.
Publicado: (2021)

Blood Type Does Not Affect Morbidity or Mortality in COVID-19 Infections, As Assessed By a Clinical Severity Scoring System
por: Thomas, Katharine E, et al.
Publicado: (2021)

Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience
por: Galvez, Carlos, et al.
Publicado: (2020)

Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients
por: Vijenthira, Abi, et al.
Publicado: (2021)

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients
por: D'Aiello, Angelica, et al.
Publicado: (2020)

Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience
por: Suleman, Adam, et al.
Publicado: (2021)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK
por: Cranmer, Holly, et al.
Publicado: (2020)

COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study
por: Ip, Andrew, et al.
Publicado: (2020)

IMMUNE THROMBOCYTOPENIA PURPURA ASSOCIATED WITH NOVEL CORONAVIRUS INFECTION
por: Camelo, R.M., et al.
Publicado: (2020)

Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome
por: Shen, Yandong, et al.
Publicado: (2021)

Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients
por: Bussini, Linda, et al.
Publicado: (2022)

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
por: Dinnessen, Manette A.W., et al.
Publicado: (2020)

Impact of the COVID-19 Pandemic on Primary Care Access for Patients with Hematologic Malignancies
por: Ling, Ying, et al.
Publicado: (2021)

Malignant DFFB isoform switching promotes leukemia survival in relapse pediatric T‐cell acute lymphoblastic leukemia
por: Enlund, Sabina, et al.
Publicado: (2022)

Social and Demographic Factors Contributing to COVID-19 Vaccine Hesitancy in Patients with Hematologic Malignancies
por: Sweiss, Karen, et al.
Publicado: (2021)

COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies
por: Goksu, Suleyman Y, et al.
Publicado: (2021)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

The added prognostic values of baseline PET dissemination parameter in patients with angioimmunoblastic T‐cell lymphoma
por: Gong, Huanyu, et al.
Publicado: (2022)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)

The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
por: Fatima, Narjis, et al.
Publicado: (2021)

A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
por: Kostakoglu, Lale, et al.
Publicado: (2023)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
por: Zhu, Jun, et al.
Publicado: (2022)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

SBNO2 is a critical mediator of STAT3-driven hematological malignancies
por: Brandstoetter, Tania, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s3hbe7jkbdthighk5rhi5pgfpe